Payment overview · 2025
General Payments
$626.77
21 reported records · 7 companies
Healthcare provider profile · identity verified
Deepa Samir Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPOTSWOOD, NJ · NPI 1134225162
Verified facts
What the public records show
CMS Open Payments records show Deepa Samir Patel, M.D. received $626.77 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 61.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $384.22 | 61.3% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $120.19 | 19.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.19 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.89 | 4.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.26 | 4.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.52 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.50 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $626.77 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.86 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.86 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $120.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 696 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 104 |
| Eliquis | Apixaban | 458 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 457 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 351 | 71 |
| Mirtazapine | Mirtazapine | 289 | 45 |
| Metformin Hcl | Metformin Hcl | 281 | 69 |
| Furosemide | Furosemide | 276 | 71 |
| Gabapentin | Gabapentin | 266 | 62 |
| Losartan Potassium | Losartan Potassium | 255 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 45 |
| Potassium Chloride | Potassium Chloride | 192 | 41 |
| Simvastatin | Simvastatin | 183 | 41 |
| Sertraline Hcl | Sertraline Hcl | 168 | 23 |
| Famotidine | Famotidine | 160 | 30 |
| Lisinopril | Lisinopril | 158 | 44 |
| Trazodone Hcl | Trazodone Hcl | 148 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 28 |
| Omeprazole | Omeprazole | 138 | 28 |
| Levetiracetam | Levetiracetam | 134 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 46 |
| Divalproex Sodium | Divalproex Sodium | 122 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 118 | 41 |
| Donepezil Hcl | Donepezil Hcl | 114 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 18 |
| Memantine Hcl | Memantine Hcl | 98 | 17 |
| Carvedilol | Carvedilol | 96 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 24 |
| Warfarin Sodium | Warfarin Sodium | 82 | suppressed |
| Januvia | Sitagliptin Phosphate | 81 | suppressed |
| Finasteride | Finasteride | 80 | 15 |
| Buspirone Hcl | Buspirone Hcl | 79 | 13 |
| Midodrine Hcl | Midodrine Hcl | 79 | 23 |
| Latanoprost | Latanoprost | 76 | 13 |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | 25 |
| Nifedipine Er | Nifedipine | 68 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 63 | 11 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Bethanechol Chloride | Bethanechol Chloride | 61 | suppressed |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Procrit | Epoetin Alfa | 61 | suppressed |
| Risperidone | Risperidone | 61 | suppressed |
| Allopurinol | Allopurinol | 60 | 15 |
| Baclofen | Baclofen | 60 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Labetalol Hcl | Labetalol Hcl | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 12 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Repaglinide | Repaglinide | 54 | 12 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 27 |
| Azithromycin | Azithromycin | 49 | 44 |
| Tramadol Hcl | Tramadol Hcl | 48 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Nystatin | Nystatin | 46 | 32 |
| Sevelamer Carbonate | Sevelamer Carbonate | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 23 |
| Hydrocortisone | Hydrocortisone | 45 | suppressed |
| Lactulose | Lactulose | 45 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | 18 |
| Ketoconazole | Ketoconazole | 42 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Folic Acid | Folic Acid | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 15 |
| Glipizide | Glipizide | 39 | suppressed |
| Insulin Lispro | Insulin Lispro | 39 | 17 |
| Methimazole | Methimazole | 38 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 35 | 18 |
| Budesonide | Budesonide | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 32 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 12 |
| Atenolol | Atenolol | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 22 |
| Prednisone | Prednisone | 29 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 13 |
| Metolazone | Metolazone | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | 11 |
| Nyamyc | Nystatin | 25 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Primidone | Primidone | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Naproxen | Naproxen | 14 | 11 |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $626.77 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, FARXIGA, Kerendia, NUCALA, OTEZLA, REPATHA, TEZSPIRE, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error